TPA lowers risk of heart failure after heart attacks
Study from Johns Hopkins shows emergency use of tissue plasminogen activator after heart attacks reduces congestive heart failure. Compared with placebo, 14 percent of TPA patients vs 33 percent of placebo patients developed heart failure in 10 days. angioplasty enhanced benefits.
MENTIONED IN THIS ARTICLE
Boston
U.S. Food and Drug Administration
New England Journal of Medicine
Alan D. Guerci
Johns Hopkins Hospital
Baltimore
Myron L. Weisfeldt
FDA approves Haemophilus influenzae type B conjugate vaccine
The FDA approves the first Haemophilus influenzae type B conjugate vaccine from Connaught Laboratories, aiming to better protect children under 2 from a meningitis form that sickens up to 10,000 yearly and kills about 500. Experts cite stronger immunity from conjugation, while some regions question prior vaccines’ effectiveness. Authorities note continued development by Praxis and Merck and unresolved regional efficacy differences.
MENTIONED IN THIS ARTICLE
New York
Afp
Food and Drug Administration
Faye Peterson
FDA
Connaught Laboratories
Swiftwater
Frank Young
U.S. Centers For Disease Control
American Academy of Pediatrics
Minnesota
Minnesota State Health Department
Michael Osterholm
Minnesota Health Department
Praxis Biologics
Beverly Hills
Calif
Merck Sharp & Dohme
West Point
Osterholm
Interscience Conference
Connaught, Praxis
Lederle Laboratories
Pearl River
N.Y
Brown
Also Mentioned on This Page
Raulty
Phe
Aspbery
Design Resource Architects
Erry i Qarincass
Cele